Prescription Drugs: FDA Has Met Most Performance Goals for Reviweing Application
||U.S. Government Accountability Office, |
|Publication Date:||Aug 2013|
| Publisher:||CreateSpace Independent Publishing Platform|
| Book Format:||Paperback|
|List Price:||USD $15.99|
| Book Description: |
Drug applications-including NDAs, BLAs, and efficacy supplements-are reviewed primarily by FDA's Center for Drug Evaluation and Research (CDER), with a smaller proportion reviewed by the Center for Biologics Evaluation and Research (CBER).